Guidelines for treatment of drug-susceptible tuberculosis and patient care: 2017 update. Document WHO/HTM/TB/2017.05. Geneva, World Health Organization, 2017. Available from: http:// apps.who.int/iris/bitstream/10665/255052/1/9789241550000-eng.pdf...
F Betsy - 《Clinical Infectious Diseases An Official Publication of the Infectious Diseases Society of America》 被引量: 21发表: 2013年 Assessment of Caspofungin use at a Tertiary Teaching Hospital and compliance with IDSA guidelines and FDA labelings Objective:The aim of this study is to evaluate...
The Phase 3 randomized controlled trial, TBTC Study 31/ACTG A5349 (NCT02410772) demonstrated that a 4-month rifapentine-moxifloxacin regimen for drug-susceptible pulmonary tuberculosis was safe and effective. The primary efficacy outcome was 12-month tuberculosis disease free survival, while the prima...
Z. et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat. Med. 24, 1708–1715 (2018). Article CAS PubMed PubMed Central Google Scholar Lange, C. et al. Management of drug-resistant tuberculosis. Lancet 394, 953–966 (2019...
First, we have confirmed that cases with drug-susceptible strains of M tuberculosis respond better to SCC than cases with resistant strains. Second, multidrug-resistant TB cases have the highest rates of death and treatment failure in both new and retreatment cases. Third, any isoniazid resistance...
Drug resistance Diagnostics Regimen selection Treatment outcomes Cost effectiveness 1. Introduction Each year, more than half a million new cases of rifampin-resistant tuberculosis – including multidrug-resistant tuberculosis (MDR TB, resistant to rifampin and isoniazid) – occur worldwide. These strains...
Drug therapy For initial empiric treatment of TB, start patients on a 4-drug regimen: isoniazid, rifampin, pyrazinamide, and ethambutol. Once the TB isolate is known to be fully susceptible, ethambutol can be discontinued. [5] Patients with TB receiving pyrazinamide should undergo baseline and ...
drug in the combination is promoted. In the case of MDR-TB there is a poor prognosis and treatment is further complicated byside effectsand the use of relatively ineffective and very expensive alternative drugs which could result in chemotherapy being impossible to afford in many countries of the...
of drug therapy. Such adjustments may not be required for otherwise healthy individuals who are responding to the standard, four-drug TB regimens. However, some patients are slow to respond to treatment, have drug-resistant TB, are at risk of drug-drug interactions or have concurrent disease ...
Since the advent of effective antibiotic therapy, there has been an enduring quest to shorten the length of treatment required to reliably cure tuberculosis (TB)1,2,3,4,5. Current standard regimens range in duration from 6 months for drug-susceptible TB to years for some drug-resistant TB in...